article thumbnail

Hospitals and Medical Device Manufacturers Must Work Together on Cybersecurity

MedCity News

Greater collaboration among healthcare providers, medical device manufacturers, and lawmakers and regulators will lead to predictability and consistency in cybersecurity management. Together, we can make even greater strides toward patient safety and a more secure and sustainable healthcare system.

article thumbnail

America’s healthcare costs are in deep crisis

World of DTC Marketing

Healthcare providers make more money treating poor health than preventing it. A car manufacturer should not overpay for care any more than it overpays for steel” What is Pharma’s responsibility? The explanation of why is actually quite simple. Where is the ROI for a company to promote exercise and healthy diets?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharma Sales in Malaysia: The Role of Drug Access Programs in Providing Essential Medications

Contrarian Sales Techniques

For pharma sales reps, these programs are not just tools for market penetration – they’re lifelines that improve healthcare accessibility across the country. Drug access programs are initiatives, often run by pharmaceutical companies in collaboration with healthcare providers, to make essential medications more accessible to patients.

Sales 52
article thumbnail

GUEST COMMENTARY – Beyond the Script: Branding Patient Support

PM360

For prescription drugs, this takes the shape of patient support programs (PSPs): opt-in enabled, manufacturer-provided services in the form of live support, AI support, educational tools, and financial resources, typically offered to eligible prescribed patients at no additional cost.

article thumbnail

Patent expiration to drive biosimilars market expansion to 2032

European Pharmaceutical Review

Expirations of biologic patents has enabled manufacturers to enter the market and offer lower-cost alternatives of these drugs, according to the report. In-house manufacturing has become “increasingly popular” with biosimilar companies, according to the report. million by 2032, at 17.6 percent CAGR between 2023 and 2032.

Marketing 105
article thumbnail

The Ripple Effect: How Recent U.S. Tariffs Will Impact Medical Device Sales and Manufacturing in 2025

Legacy MEDSearch

The medical device industry has long been a globalized ecosystem, with raw materials, components, and finished products crisscrossing international supply chains before reaching healthcare providers. based manufacturers relying on imported parts. A core objective of these tariffs is to bring more manufacturing back to the U.S.,

article thumbnail

Embracing digitalization in the pharmaceutical supply chain

Pharmaceutical Technology

“There are already opportunities for patients to track their health through smart medical devices sending reports directly to their healthcare provider. These healthcare providers will offer telemedicine, allowing remote patient monitoring from the comfort of the patients’ own homes. Disruptive technologies.